Vitamin D Status and Outcomes in Locally Advanced Cervical Cancer treated with chemoradiotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational cohort study enrolling women with locally advanced cervical cancer (FIGO IIB-IVA) who will receive standard definitive chemoradiotherapy. Pretreatment vitamin D is measured in serum and cervical lavage, and patients are followed to assess treatment response with pelvic MRI about five months after therapy and to monitor acute toxicity during treatment. The goal is to identify whether vitamin D status is associated with treatment response or toxicity, which could help tailor future care. All participants receive the same standard treatment including external beam radiotherapy, brachytherapy, and weekly cisplatin. The study is conducted at the University Clinical Center Kragujevac and led by the University of Kragujevac.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female patients aged 18 to 80 years.
* Histopathologically confirmed cervical cancer.
* Locally advanced disease, FIGO 2018 stage IIB to IVA.
* Eastern Cooperative Oncology Group performance status 0-1.
* Planned treatment with definitive concurrent chemoradiotherapy.
* Signed informed consent.
* Ability to comply with study procedures and follow-up visits.

Exclusion Criteria:

* Age under 18 years.
* Pregnancy or lactation.
* Previous or synchronous diagnosis of another pelvic or abdominal malignancy.
* Previous chemotherapy.
* Previous radiotherapy.
* Previous treatment with immune checkpoint inhibitors.
* Current or recent vitamin D supplementation.
* Interrupted oncological treatment.
* Failure to attend scheduled follow-up visits.
* Incomplete medical documentation.

Where it's running

• University Clinical Center Kragujevac
  Kragujevac, Šumadija, Serbia Recruiting

Study contacts

• Principal investigator: Marija Živković Radojević, MD, PhD, Radiation Oncologist — Faculty of Medical Sciences, University of Kragujevac, Serbia, University Clinical Centre Kragujevac, Center for radiation oncology
• Study coordinator: Marija Živković Radojević, MD, PhD, Radiation Oncologist
• Email: makizivkovicmarija@gmail.com
• Phone: +381658384450

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Iparomlimab/Tuvonralimab with nab-paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer

  This trial tests whether adding Iparomlimab/Tuvonralimab to nab-paclitaxel and cisplatin before surgery can shrink locally advanced cervical cancer and safely be given to adult women.

  Recruiting Phase 2 Xijing Hospital · Xi'an, Shaanxi · NCT07876154

• Patient-tailored 3D-printed ARCHITECT applicator for cervical cancer brachytherapy

  We’re testing a 3D-printed, one-time use ARCHITECT applicator to see if it safely helps deliver brachytherapy for locally advanced cervical cancer.

  Recruiting Erasmus Medical Center · Rotterdam · NCT07435987

• Nanocrystalline megestrol acetate with chemoradiation for locally advanced cervical cancer

  This Phase 1 trial tests whether taking nanocrystalline megestrol acetate by mouth can prevent or reduce weight and muscle loss in adults with locally advanced cervical cancer who are receiving concurrent chemoradiotherapy.

  Recruiting Phase 1 Second Xiangya Hospital of Central South University · Changsha, Hunan · NCT07338487

• Cadonilimab plus cisplatin given before surgery for locally advanced cervical cancer

  This study will test whether giving cadonilimab together with cisplatin before surgery helps people with resectable, locally advanced cervical cancer.

  Recruiting Phase 2 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT07104149

• Pre-surgery iparomlimab and tuvonralimab with chemotherapy for locally advanced cervical cancer

  This phase 2 trial tests whether giving iparomlimab and tuvonralimab with chemotherapy before surgery helps people with locally advanced cervical cancer shrink their tumors and improve outcomes.

  Recruiting Phase 2 Fujian Cancer Hospital · Fuzhou, Fujian · NCT07055399

• Understanding cervical cancer treatment and characteristics in Italy

  This study looks at how patients in Italy with advanced or recurring cervical cancer are treated and what their experiences are like.

  Recruiting at 10 sites MSD Italia S.r.l. · Bologna, Bologna and 10 other locations · NCT06771193

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.